Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Research & Development (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Research & Development data on record, last reported at $23.3 million in Q4 2025.

  • For Q4 2025, Research & Development rose 28.51% year-over-year to $23.3 million; the TTM value through Dec 2025 reached $85.8 million, up 16.14%, while the annual FY2025 figure was $85.8 million, 16.14% up from the prior year.
  • Research & Development reached $23.3 million in Q4 2025 per AMPH's latest filing, up from $22.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $23.3 million in Q4 2025 and bottomed at $10.8 million in Q3 2021.
  • Average Research & Development over 5 years is $18.5 million, with a median of $18.1 million recorded in 2021.
  • Peak YoY movement for Research & Development: crashed 39.02% in 2021, then soared 72.08% in 2022.
  • A 5-year view of Research & Development shows it stood at $17.3 million in 2021, then fell by 0.29% to $17.2 million in 2022, then grew by 18.47% to $20.4 million in 2023, then dropped by 11.15% to $18.1 million in 2024, then grew by 28.51% to $23.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $23.3 million in Q4 2025, $22.4 million in Q3 2025, and $20.1 million in Q2 2025.